← Leaderboards
Christine Brown
Beckman Research Institute/City Of Hope
$5,264,024
Attributed
$11,634,990
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,034,990 · 4
FDA$600,000 · 1
By mechanism
R01$10,895,490 · 4
R21$739,500 · 1
Top collaborators
- Behnam Badie14 shared
- Jennifer M Munson5 shared
- Russell Christian Rockne5 shared
- John Charles Williams3 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Behnam Badie$11,237,051
- Christiane Querfeld$3,066,660
- Zijie Sun$18,720,797
- Xiuli Wang$2,702,470
- Saul Priceman$1,392,931
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteInnovationResponseImmunotherapyTumorChimeric Antigen ReceptorSafetyCerebrospinal FluidCellsChimeric Antigen Receptor T CellsSolid NeoplasmCar T Cell TherapyImmuneProgramsCitiesGlioblastomaMediatingAntigensTranslatingNeoplastic CellIn VivoBaseReceptorCharacteristics
Grant awards (22)
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$652,200
R01 · FY2025 · NS
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$809,915
R01 · FY2024 · CA · contact PI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$711,759
R01 · FY2024 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$637,292
R01 · FY2024 · NS
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$734,238
R01 · FY2023 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$664,834
R01 · FY2023 · NS
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$469,554
R01 · FY2023 · CA · contact PI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$734,238
R01 · FY2022 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$671,774
R01 · FY2022 · NS
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$1
R01 · FY2022 · CA · contact PI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$749,221
R01 · FY2021 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$694,724
R01 · FY2021 · NS
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,841
R01 · FY2021 · CA · contact PI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma$768,221
R01 · FY2020 · CA · contact PI
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,839
R01 · FY2020 · CA · contact PI
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma$665,839
R01 · FY2019 · CA · contact PI
In situ Imaging of CAR T-cells$258,825
R21 · FY2017 · CA
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2017 · FD
In situ Imaging of CAR T-cells$258,825
R21 · FY2016 · CA
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2016 · FD
In situ Imaging of CAR T-cells$221,850
R21 · FY2015 · CA
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma$200,000
R01 · FY2015 · FD